NLRP3 and osteosarcoma: Recently, Santos‐Ruiz laboratory revealed synergic antitumor effects of Oridonin and doxorubicin in human osteosarcoma cells, although mechanistic evidences that link this outcome with NLRP3 inflammasome are still missing [197].